 |
市场调查报告书
商品编码
1890948
医用氢可酮市场：按给药途径、用途、最终用户、製造商、规格、患者年龄层、通路和地区划分Medical Morphine Market, By Route of Administration, By Application, By End User, By Manufacturing Origin, By Strength, By Patient Age Group, By Distribution Channel, By Geography |
||||||
预计到 2025 年，医用氢可酮市场价值将达到 251.4 亿美元，到 2032 年将达到 422.5 亿美元，2025 年至 2032 年的复合年增长率为 7.7%。
| 报告覆盖范围 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2024 | 2025年市场规模： | 251.4亿美元 |
| 历史数据时期： | 2020年至2024年 | 预测期： | 2025年至2032年 |
| 预测期（2025-2032年）复合年增长率： | 7.70% | 2032 年的预测值： | 422.5亿美元 |
全球医用氢可酮市场是製药业的重要组成部分，主要集中在氢可酮类药物的生产、分销和应用，用于疼痛管理和安宁疗护。氢可酮是一种植物来源的天然鸦片生物碱，是全球临床上治疗重度疼痛的黄金标准。这种重要的治疗药物在治疗急性和慢性疼痛方面发挥着至关重要的作用，尤其是在术后护理、癌症治疗和临终关怀等领域。
医用氢可酮市场涵盖多种剂型，包括速释片、缓释性製剂、注射液和口服液，每种剂型都旨在满足特定的患者需求和临床要求。医疗专业人员高度依赖氢可酮强大的止痛特性来改善患者的生活质量，并确保有效的疼痛管理通讯协定。市场的重要性远不止于产生收入；它直接影响全球医疗保健成果和病患福祉。儘管面临监管挑战和对阿片类药物成瘾的担忧，医用氢可酮因其在控制重度疼痛方面无与伦比的疗效，在现代医学中仍然不可或缺。随着製药技术的进步、给药机制的改进和安全性的提升，该行业不断发展，以在保持治疗效果的同时，最大限度地降低潜在风险。
市场动态
全球医用氢可酮市场受多种强劲因素驱动，在国际医疗保健体系中持续成长。主要驱动因素包括全球慢性疼痛疾病、癌症病例和外科手术的增加，对有效的疼痛管理解决方案产生了显着需求。全球人口老化进一步加剧了这一需求，因为老年人在整个医疗保健过程中往往需要更密集的疼痛管理介入。此外，新兴经济体医疗基础设施的改善和疼痛管理疗法的普及也显着促进了市场扩张。医护人员对正确疼痛管理通讯协定和病患治疗舒适度重要性的认识不断提高，也促使氢可酮在临床应用中日益普及。
然而，该市场面临许多限制因素，包括严格的鸦片类药物处方法规结构、日益严重的鸦片类药物成瘾和依赖问题，以及全球监管机构日益严格的审查。阿片类药物危机导致医疗系统实施了更严格的处方指南，这可能会抑制市场成长。此外，替代性疼痛管理疗法和非鸦片类止痛药的出现，对传统的氢可酮类药物治疗构成了竞争挑战。儘管有这些限制因素，市场格局仍蕴藏着巨大的机会。开发防滥用製剂为市场成长提供了一个有前景的途径，同时也能解决安全问题。在发展中地区扩大医疗保健服务覆盖范围，蕴藏着巨大的市场潜力，尤其是在疼痛管理基础设施尚未完善的地区。
本次调查的主要特点
- 本报告对全球医用氢可酮市场进行了详细分析，以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和復合年增长率%。
- 我们将重点介绍各个细分市场的潜在商机，并说明该市场具有吸引力的投资提案矩阵。
- 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 本报告根据以下参数对全球医用氢可酮市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
- 本报告的研究结果将使负责人和经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 这份全球医用氢可酮市场报告的目标受众是该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
- 相关人员可以透过各种用于分析全球医用氢可酮市场的策略矩阵轻鬆做出决策。
目录
第一章 研究目标与前提条件
- 调查目的
- 先决条件
- 简称
第二章 市场范围
- 报告概述
- 市场定义和范围
- 执行摘要
第三章 市场动态、监管与趋势分析
- 市场动态
- 司机
- 抑制因素
- 机会
- 影响分析
- 重大进展
- 法规环境
- 产品上市及核准
- PEST分析
- 波特分析
- 併购趋势
- 产业趋势
4. 2020-2032年全球医用氢可酮市场（依给药途径划分）
- 口服
- 肠外
- 其他给药途径（经皮、栓剂给药、鼻腔给药等）
5. 2020-2032年全球医用氢可酮市场（依应用领域划分）
- 癌症相关疼痛管理
- 急性疼痛（术后、外伤、心肌梗塞）
- 慢性疼痛（关节炎、肌肉骨骼疾病）
- 安宁疗护与临终关怀
- 其他用途（例如，止泻、止咳）
6. 2020-2032年全球医用氢可酮市场（依最终用户划分）
- 医院和诊所
- 门诊手术中心
- 居家医疗/家庭保健机构
- 其他（復健中心、安宁疗护中心）
7. 2020-2032年全球医用氢可酮市场（按製造商划分）
- 品牌产品
- 非专利的
8. 2020-2032年全球医用氢可酮市场（依浓度划分）
- 低剂量（10毫克或更少）
- 中等剂量（10毫克以上至30毫克以下）
- 高剂量（>30毫克）
9. 2020-2032年全球医用氢可酮市场（依病患年龄层划分）
- 儿童
- 成人
- 老年人
10. 2020-2032年全球医用氢可酮市场（依通路划分）
- 医院药房
- 零售药房
- 网路药房
11. 2020-2032年全球医用氢可酮市场（按地区划分）
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲国家
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
- 非洲
- 南非
- 北非
- 中非
第十二章 竞争格局
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals plc
- Sun Pharmaceutical Industries Ltd.
- Johnson and Johnson
- Viatris Inc.
- Hikma Pharmaceuticals plc
- Aurobindo Pharma Ltd.
- Endo International plc
- Mylan NV（now Viatris）
- Merck KGaA
- Bristol Myers Squibb Company
- Grunenthal GmbH
- Sanofi SA
- AbbVie Inc.
第十三章 分析师建议
- 机会
- 分析师观点
- Coherent Opportunity Map
第十四章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Medical Morphine Market is estimated to be valued at USD 25.14 Bn in 2025 and is expected to reach USD 42.25 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 25.14 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.70% | 2032 Value Projection: | USD 42.25 Bn |
The global medical morphine market represents a critical segment within the pharmaceutical industry, primarily focused on the production, distribution, and utilization of morphine-based medications for pain management and palliative care. Morphine, a naturally occurring opioid alkaloid derived from the opium poppy plant, serves as the gold standard for severe pain relief in clinical settings worldwide. This essential therapeutic agent plays an indispensable role in managing acute and chronic pain conditions, particularly in post-surgical care, cancer treatment, and end-of-life care scenarios.
The medical morphine market encompasses various formulations including immediate-release tablets, extended-release formulations, injectable solutions, and oral liquids, each designed to meet specific patient needs and clinical requirements. Healthcare providers rely heavily on morphine's potent analgesic properties to improve patient quality of life and ensure effective pain management protocols. The market's significance extends beyond mere revenue generation, as it directly impacts global healthcare outcomes and patient welfare. Despite regulatory challenges and concerns surrounding opioid dependency, medical morphine remains irreplaceable in modern medicine due to its unparalleled efficacy in severe pain management. The industry continues to evolve with advancing pharmaceutical technologies, improved delivery mechanisms, and enhanced safety profiles to maintain therapeutic benefits while minimizing potential risks.
Market Dynamics
The global medical morphine market is driven by several compelling factors that sustain its growth trajectory across international healthcare systems. The primary driver stems from the increasing prevalence of chronic pain conditions, cancer cases, and surgical procedures worldwide, creating substantial demand for effective pain management solutions. An aging global population further amplifies this demand, as elderly individuals typically require more intensive pain management interventions throughout their healthcare journey. Additionally, improved healthcare infrastructure in emerging economies and enhanced access to pain management therapies contribute significantly to market expansion. Growing awareness among healthcare professionals regarding proper pain management protocols and the importance of patient comfort during treatment has led to increased morphine utilization in clinical settings.
However, the market faces considerable restraints including stringent regulatory frameworks governing opioid prescriptions, growing concerns about opioid addiction and dependency, and increasing scrutiny from regulatory authorities worldwide. The opioid crisis has prompted healthcare systems to implement more restrictive prescribing guidelines, potentially limiting market growth. Furthermore, the emergence of alternative pain management therapies and non-opioid analgesics presents competitive challenges to traditional morphine-based treatments. Despite these restraints, significant opportunities exist within the market landscape. The development of abuse-deterrent formulations presents promising avenues for market growth while addressing safety concerns. Expanding healthcare access in developing regions offers untapped market potential, particularly in areas where pain management infrastructure is still developing.
Key Features of the Study
- This report provides in-depth analysis of the global medical morphine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global medical morphine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals plc, Sun Pharmaceutical Industries Ltd., Johnson and Johnson, Viatris Inc., Hikma Pharmaceuticals plc, Aurobindo Pharma Ltd., Endo International plc, Mylan N.V. (now Viatris), Merck KGaA, Bristol Myers Squibb Company, Grunenthal GmbH, Sanofi S.A., and AbbVie Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global medical morphine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global medical morphine market
Market Segmentation
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Other routes (transdermal, suppository, intranasal, etc.)
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Cancer related pain management
- Acute pain (post surgery, trauma, myocardial infarction)
- Chronic pain (arthritis, musculoskeletal disorders)
- Palliative and end of life care
- Other applications (e.g., diarrhea suppression, cough suppression)
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Homecare/Home Healthcare Settings
- Other (rehabilitation centers, hospices)
- Manufacturing Origin Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- Strength Insights (Revenue, USD Bn, 2020 - 2032)
- Low dose (e.g.<=10 mg)
- Medium dose (e.g.10 mg to <=30 mg)
- High dose (30 mg)
- Patient Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals plc
- Sun Pharmaceutical Industries Ltd.
- Johnson and Johnson
- Viatris Inc.
- Hikma Pharmaceuticals plc
- Aurobindo Pharma Ltd.
- Endo International plc
- Mylan N.V. (now Viatris)
- Merck KGaA
- Bristol Myers Squibb Company
- Grunenthal GmbH
- Sanofi S.A.
- AbbVie Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Medical Morphine Market, By Route of Administration
- Global Medical Morphine Market, By Application
- Global Medical Morphine Market, By End User
- Global Medical Morphine Market, By Manufacturing Origin
- Global Medical Morphine Market, By Strength
- Global Medical Morphine Market, By Patient Age Group
- Global Medical Morphine Market, By Distribution Channel
- Global Medical Morphine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Medical Morphine Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other routes (transdermal, suppository, intranasal, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Medical Morphine Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Cancer related pain management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Acute pain (post surgery, trauma, myocardial infarction)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Chronic pain (arthritis, musculoskeletal disorders)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Palliative and end of life care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other applications (e.g., diarrhea suppression, cough suppression)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Medical Morphine Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare/Home Healthcare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other (rehabilitation centers, hospices)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Medical Morphine Market, By Manufacturing Origin, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Medical Morphine Market, By Strength, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Low dose (e.g.<=10 mg)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Medium dose (e.g.>10 mg to <=30 mg)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- High dose (>30 mg)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Medical Morphine Market, By Patient Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Medical Morphine Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Medical Morphine Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mallinckrodt Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Endo International plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V. (now Viatris)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Grunenthal GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
氢可酮市场规模、份额和成长分析（按形式、分销管道、应用、最终用户和地区）- 2025-2032 年产业预测
吗啡药物市场 - 全球产业规模、份额、趋势、机会和预测，按产品、应用、地区和竞争细分，2019-2029F![吗啡药物市场规模 - 按剂型（注射、口服）、应用（疼痛管理 [癌症、神经性、骨关节炎]、安宁疗护、止泻药、感冒和咳嗽、麻醉）、配销通路、最终用途和预测，2024年 - 2032](/sample/img/cover/42/default_cover_gmi.png)
吗啡药物市场规模 - 按剂型（注射、口服）、应用（疼痛管理 [癌症、神经性、骨关节炎]、安宁疗护、止泻药、感冒和咳嗽、麻醉）、配销通路、最终用途和预测，2024年 - 2032
吗啡药物市场，按剂型、按应用、配销通路、最终用途、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测吗啡市场报告：2030 年趋势、预测与竞争分析